Ambrocol

Quick links to important sections

Ambrocol

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ambrocol

What is Ambrocol?

Ambrocol is a pharmacological agent classified as a mucolytic. It is primarily used to manage respiratory conditions characterized by excessive or thickened mucus production. By targeting the structure of bronchial secretions, it helps to facilitate the clearance of the airways.

Mechanism of Action

Ambrocol works by increasing the production of serous pulmonary surfactant and stimulating ciliary activity. This process results in several key physiological changes:

  • Mucus Thinning: It breaks down the chemical bonds of thick mucus, reducing its viscosity.
  • Improved Clearance: By enhancing the movement of the cilia—the tiny hair-like structures lining the respiratory tract—it aids the body in moving mucus upward and out of the lungs.
  • Surfactant Regulation: It promotes the secretion of surfactant, which helps prevent the mucus from adhering to the bronchial walls.

Primary Uses

This medication is typically utilized in the context of both acute and chronic respiratory disorders. It is often integrated into the management of conditions where phlegm production is a significant symptom, such as:

  • Acute bronchitis
  • Chronic obstructive pulmonary disease (COPD)
  • Tracheobronchitis
  • Respiratory distress syndrome

By easing the removal of secretions, Ambrocol supports the natural respiratory process and helps maintain clearer air passages.

What side effects are possible with Ambrocol?

Possible side effects and safety information

The safety profile of Ambrocol is documented through official regulatory classifications, outlining adverse reactions associated with its dual components: Ambroxol and Clenbuterol.

Frequency-Classified Adverse Reactions

Adverse effects are categorized by frequency, based on reports summarized in official prescribing information:

Frequency Category Associated Adverse Reactions (Examples)
Common Dysgeusia (taste disturbance), pharyngeal/oral hypoesthesia (numbness), nausea, diarrhea.
Uncommon Vomiting, abdominal pain, dyspepsia (indigestion), dry mouth, fever.
Rare Hypersensitivity reactions, rash, urticaria (hives), heartburn.
Not Known Anaphylactic reactions, anaphylactic shock, angioedema, pruritus, Severe Cutaneous Adverse Reactions (SCARs), palpitations, tachycardia.

System-Organ-Class Groups

Documented reactions are grouped by the affected body system, including Gastrointestinal disorders (e.g., vomiting, dry mouth), Nervous system disorders (e.g., headache, dizziness), Cardiac disorders (e.g., tachycardia, palpitations), and Immune system disorders.

Serious Adverse Reactions and Safety Constraints

Regulatory documents explicitly list Anaphylactic reactions, including anaphylactic shock and angioedema, as serious adverse reactions. Specific Severe Cutaneous Adverse Reactions (SCARs), such as Stevens-Johnson syndrome (SJS) / Toxic Epidermal Necrolysis (TEN), are also documented.

Population-specific safety constraints are noted for use in individuals with severe renal or hepatic impairment due to the potential for metabolite accumulation. Use during lactation and the first trimester of pregnancy is not recommended. Furthermore, a safety restriction exists against combining Ambrocol with certain cough suppressants due to the documented risk of serious airway obstruction from mucus accumulation.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory documents define Ambrocol overdosage as a potentially severe and life-threatening event requiring immediate medical intervention. The documented clinical manifestations are primarily exaggerated effects of the beta2-adrenergic agonist component, Clenbuterol.

Overdose manifestations include systemic effects such as Tachycardia (rapid heart rate), Palpitations, Tremors, Anxiety, and Agitation. Severe outcomes listed in regulatory information include Myocardial Ischemia, Atrial Fibrillation, Seizures, and Cardiac Arrest.


Mandatory Emergency Actions

Action Required Official Regulatory Guidance
Urgent Help Seek immediate medical attention or contact emergency services must be done for any suspected overdose due to the risk of severe toxicity.
Monitoring Continuous cardiac monitoring and hospital admission are required for patients with severe symptoms or evidence of cardiotoxicity.
Antidote No specific antidote is known for the highly toxic beta2-adrenergic component.

Supportive Care: Management is officially defined as symptomatic and supportive treatment. This may involve procedures such as Potassium Supplementation to correct documented Hypokalemia, and the use of Selective beta-Blockers to manage severe cardiac effects, when indicated by the treating physician. These official instructions underscore that management must be conducted in a monitored clinical setting.

Therapeutic Uses of Ambrocol

What Ambrocol Treats: Main Uses and Benefits

Ambrocol is a mucolytic agent primarily used to manage respiratory conditions characterized by the production of thick, viscous mucus. By altering the structure of bronchial secretions, it helps facilitate the natural clearance processes of the respiratory tract.

Primary Indications

Ambrocol is utilized in the management of both acute and chronic respiratory disorders, including:

  • Acute Bronchitis: It is used during the sudden onset of bronchial inflammation to assist in thinning mucus, making it easier to expel through coughing.
  • Chronic Bronchitis: In long-term inflammatory conditions, it helps manage the persistent production of phlegm.
  • Chronic Obstructive Pulmonary Disease (COPD): It may be used as part of a broader management strategy to improve airway clearance in patients with chronic airflow obstruction.
  • Bronchial Asthma: When asthma is accompanied by abnormal mucus secretion and impaired mucus transport, Ambrocol can support the clearing of the airways.
  • Bronchiectasis: It is used to help clear the excessive and often thick mucus that accumulates in the permanently widened airways characteristic of this condition.

Therapeutic Benefits

Ambrocol works through several physiological mechanisms to provide respiratory support:

  • Mucolytic Action: It breaks down the chemical bonds of the fibers within the mucus, reducing its viscosity and stickiness.
  • Secretomotoric Effect: It stimulates the activity of the cilia—the tiny hair-like structures lining the airways—which increases the speed at which mucus is transported out of the lungs.
  • Surfactant Stimulation: It encourages the production of pulmonary surfactant, a substance that prevents the airways from sticking together and further aids in the movement of secretions.
  • Ease of Expectoration: By thinning the mucus and improving its transport, the effort required to clear the throat and chest is reduced, which can help alleviate the discomfort associated with a productive cough.

Eligibility and Restrictions for Use

Who Can and Cannot Use Ambrocol?

The population eligibility for using Ambrocol (Ambroxol + Clenbuterol) is defined by official regulatory documents through mandatory exclusions and conditional use requirements.

Contraindicated Populations (Must Not Use)

Use is strictly contraindicated for individuals with known hypersensitivity to Ambroxol, Clenbuterol, or any of the formulation’s excipients. Regulatory labeling prohibits use in patients with specific severe pre-existing conditions, including tachyarrhythmia, hypertrophic obstructive cardiomyopathy, and untreated thyrotoxicosis.


Age and Physiological Restrictions

  • Pediatric Use: The medicine is contraindicated in different subsets of the pediatric population, typically below a specified age threshold (e.g., 6 or 12 years).
  • Pregnancy and Lactation: Use is not recommended during the first trimester of pregnancy or for nursing mothers (lactation). Conditional use may be permitted in the second and third trimesters if the potential benefit justifies the risk.

Conditional Use and Comorbidities

Special caution and restricted use are required for patients with severe heart disease (such as recent acute myocardial infarction), severe renal impairment, hepatic impairment, uncontrolled diabetes mellitus, narrow-angle glaucoma, or a history of gastric or duodenal ulcers.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines the officially documented interaction patterns for Ambrocol, based strictly on government regulatory labeling for its active components, Ambroxol and Clenbuterol.

Interaction Scope

Property Official Regulatory Statement
Medicinal product categories with documented interactions Antitussives (Cough Suppressants), Beta-Adrenergic Receptor Antagonists (Beta-Blockers), Non-Potassium Sparing Diuretics, and specific Antibiotics.
Mechanistic basis of interactions Pharmacodynamic antagonism (Beta-Blockers); Pharmacodynamic reinforcement (increased hypokalemia risk with Diuretics); Altered drug distribution (uparrow antibiotic concentration in lung tissue).
Timing-based interaction rules None explicitly stated in core regulatory summaries that mandate a specific administration time separation window.
Population-specific interaction notes Accumulation of Ambroxol metabolites is expected in patients with severe renal or hepatic impairment, requiring cautious use.

Official Interaction Statements

  • Co-administration with antitussives (e.g., Codeine, Dextromethorphan) is documented as not recommended due to the risk of accumulation of bronchial secretions in the respiratory tract.
  • Beta-Blockers may reduce the therapeutic efficacy of the Clenbuterol component by pharmacodynamic antagonism, diminishing its bronchodilatory action.
  • Co-administration with non-potassium sparing diuretics is associated with a documented increase in the risk of hypokalemia (low serum potassium levels).
  • Ambroxol has been shown to increase the concentration of specific antibiotics (e.g., Amoxicillin, Erythromycin, Doxycycline) in pulmonary tissue and secretions.

These statements define the product's interaction structure based on the pharmacodynamic risks of its Clenbuterol component and the altered tissue distribution caused by its Ambroxol component, as mandated by official government drug labels.

Mechanism of Action

Autonomic Modulation for Airway Relaxation

The Clenbuterol component functions as an agonist by selectively activating beta2-Adrenergic Receptors ( B2 -AR) located on the smooth muscle of the bronchi. This activation initiates a G s -protein-coupled cascade that increases intracellular cyclic AMP ( cAMP) levels. This biochemical change modulates the activity of Myosin Light Chain Kinase ( MLCK), resulting in a decrease in muscle tension and a subsequent change to the air passage diameter and pulmonary resistance.

Biochemical Action on Secretion Viscosity

The Ambroxol component, a secretolytic agent, stimulates Type II Pneumocytes to increase the secretion of pulmonary surfactant. Surfactant reduces the surface tension and adhesiveness of respiratory secretions. Additionally, Ambroxol promotes the depolymerization of mucopolysaccharide fibers, leading to a reduction in mucus viscosity.

Coordinated Enhancement of Mucus Clearance

These two mechanisms converge to establish a synergistic effect. The Clenbuterol-induced bronchodilation structurally provides a path, which combines with the Ambroxol-driven mucus thinning and ciliary stimulation. This coordinated enhancement accelerates the body's natural mucociliary transport, resulting in the facilitation of mobilized secretions.

Dosage and Administration Information

Ambrocol is administered solely via the oral route, available as both tablets and an oral solution (syrup). The use of the medicine follows a specific protocol defined by regulatory documents, which centers on a fixed-interval schedule to manage the dual active components. For adults, the standard regimen involves taking one unit, typically containing 30 mg of Ambroxol Hydrochloride and 20 mcg of Clenbuterol Hydrochloride, on a twice-daily basis.

The core procedural instruction requires that the two daily doses be separated by an approximate 12 hour interval. This precise timing is necessary to mitigate the potential for accumulation of the long-acting bronchodilator component over time, thereby ensuring the total daily dose does not exceed 60 mg of Ambroxol and 40 mcg of Clenbuterol. Administration is generally independent of food, and the solid dosage form is intended to be swallowed with water.

The use of this combination product is designated as short-term, intended to be carried out over a limited duration, often a course lasting approximately 7 to 10 days for acute management. Official guidance also addresses specific populations, indicating that adjustments to the standard frequency or dose may be required for individuals with severe hepatic (liver) or renal (kidney) impairment. The overall usage structure emphasizes strict adherence to the defined dose and time separation.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Ambrocol


Evidence for Use in Bronchopulmonary Conditions

Research explored the patterns observed when Ambrocol was evaluated in settings involving abnormal mucus secretion and difficulty with expectoration. Studies included Randomized Controlled Trials (RCTs) where one group received the drug and another received a placebo or a different intervention; these studies monitored the changes observed over defined time intervals. The research examined patient-reported outcomes describing perceived discomfort, such as cough intensity and frequency, and how properties of sputum were measured over the study period. Findings describe patterns observed in the studies over short-term follow-up periods, contributing to the broader evidence landscape.


Evidence for Use in Parkinson's Disease (Investigational Use)

Ambrocol was studied for its use in Parkinson's Disease (PD) through several early-phase clinical trials. Research examined individuals with mild to moderate PD, including a specific subgroup defined by the GBA1 gene mutation status. The research explored outcomes related to systemic or functional imbalance, specifically monitoring changes in the Glucocerebrosidase (GCase) enzyme activity. Data show patterns related to measured increased GCase enzyme activity in the cerebrospinal fluid was observed in some studies. These reported observations are considered preliminary, and data are still emerging from these trials.


Understanding the Certainty and Limitations of the Evidence

Evidence quality varies across studies. Some research involves controlled clinical trials in its primary area of study, while certainty remains low for its investigational use in PD because data are still emerging from early-phase trials. Long-term outcomes are not fully established regarding the stability of patterns observed over extended periods. For all uses, data for certain groups remain insufficient, particularly for pregnant populations and those with complex co-occurring medical conditions. It is important to understand that the findings describe group patterns, not personal outcomes.

Key Studies & References

  1. Ambroxol for the treatment of patients with Parkinson's disease with and without GBA1 mutations: a Phase 2, randomised, double-blind, placebo-controlled trial

Frequently Asked Questions (FAQ)

Common questions about Ambrocol (FAQ)

Q: What is the main reason doctors prescribe Ambrocol?

The primary purpose defined in official product labeling is the symptomatic treatment of specific respiratory conditions. This combination product is approved for use in diseases characterized by both airway narrowing and pathological mucus accumulation. The dual mechanism aims to support the body's natural mucociliary transport.

Q: Is Ambrocol the same type of medicine as [similar drug name]?

Ambrocol is classified as a synthetic combination product that contains two distinct active ingredients. The formulation consists of a bronchodilator ingredient, which helps relax the airways, and a secretolytic ingredient, which helps thin mucus. This dual-component profile defines its pharmacological classification and function.

Q: How quickly should someone expect Ambrocol to start working?

The active component, Ambroxol, which addresses mucus thinning, has an onset of action sometimes stated in official documents as being about 30 minutes following oral administration. Official information focuses on the timing needed to achieve the full therapeutic effect throughout the short-term treatment course.

Q: Can Ambrocol cause long-term problems or side effects?

Official evidence for Ambrocol is primarily based on short-term use and trials, aligned with its typical acute treatment course (7–10 days). Studies have monitored patterns observed over short-term periods. Therefore, regulatory documents indicate that long-term outcomes and potential issues are not fully established.

Q: Is it normal to feel [vague symptom, e.g., slightly dizzy] after starting Ambrocol?

The official safety documentation includes adverse reactions related to the nervous system. These documented reactions may include dizziness and headache, which are patterns observed in clinical reporting. The official information provides a descriptive list of known side effect patterns.

Q: Why do some people say Ambrocol makes them feel [vague sensation, e.g., tired]?

Official documents listing adverse reactions sometimes include effects related to the central nervous system. These documented effects may include tiredness or weakness (medically termed asthenia), dizziness, and headache. The official information provides a descriptive list of known side effect patterns.

Q: Does Ambrocol interact with common pain relievers like Tylenol or Advil?

The official drug interaction section explicitly lists categories like antitussives, Beta-Blockers, and certain antibiotics as having documented interactions. While specific over-the-counter pain relievers are not typically specified, the labeling indicates that all concomitant medication use should be disclosed for review.

Q: Can older adults safely use Ambrocol?

Regulatory warnings advise caution for any patient with severe hepatic (liver) or renal (kidney) impairment, which are conditions more common in older adults. However, regulatory documents do not contain explicit separate dosage or safety statements specifically for the general geriatric population.

Q: What happens if I forget to take a dose of Ambrocol?

Regulatory documents typically contain statements that indicate that if a dose is missed, the next scheduled dose should be taken at the correct time. Official labeling contains warnings against taking a double dose to compensate for a forgotten one.

Q: Does using Ambrocol affect my ability to drive or operate machinery?

Official safety documents related to post-marketing data and clinical studies often state that there is no known evidence of the medicine impairing the ability to drive or operate machinery. The official information is descriptive and does not list any specific restrictions.

Q: Is it possible to develop a tolerance to Ambrocol over time?

Official documents for the Clenbuterol component frequently address the potential for receptor desensitization or tolerance developing over time. The official label indicates a strict adherence to the defined dose and time separation is necessary to mitigate these pharmacological issues.

Q: Can I take vitamins or herbal supplements while using Ambrocol?

Official patient information contains general warnings regarding the combined use of any over-the-counter products, including vitamins and herbal supplements. The labeling indicates that full disclosure of all concomitant product use is necessary.

Q: What should I do if a side effect of Ambrocol seems severe?

Official regulatory warnings describe the documented conditions under which immediate cessation of use is necessary. These warnings relate to signs of severe adverse reactions, which include allergic reactions (like anaphylactic shock) or severe skin lesions (SCARs).

Q: Does Ambrocol require any special testing before starting it?

Product information states that caution is required for patients with pre-existing conditions like severe hepatic (liver) or renal (kidney) impairment. Regulatory guidelines note that appropriate monitoring of these systems is a necessary consideration before use.

Q: Is it okay to drink coffee while taking Ambrocol?

Official product labeling does not typically list coffee or caffeine as a direct interaction. However, the Clenbuterol component is classified as a sympathomimetic agent, and general caution is noted regarding combining it with other substances that may have stimulating effects.

Q: Can Ambrocol affect mood or cause feelings of anxiety?

The Clenbuterol component, a beta-agonist, is known to have stimulating effects on the central nervous system. As documented in related adverse reaction lists, this may include reports of psychiatric or nervous system disorders such as restlessness, agitation, or anxiety.

Q: Are there any major drug interactions with common anti-depressants or sleep aids?

The official interaction section lists drug classes like Beta-Blockers and diuretics. While specific psychotropic medications like anti-depressants or sleep aids are not always explicitly named, general cautions may exist for CNS-acting drugs or those that can affect electrolyte balance.

Q: Can people with [broad health issue, e.g., high blood pressure] use Ambrocol?

Official documents strictly prohibit the use of Ambrocol in patients with certain severe pre-existing heart conditions, such as tachyarrhythmia or hypertrophic obstructive cardiomyopathy. Special caution is also noted for those with severe heart disease or uncontrolled diabetes. The official materials define strict boundaries for who can or cannot use the medicine based on pre-existing health issues.

Q: Is Ambrocol used for both chronic and short-term conditions?

The approved therapeutic use for Ambrocol is typically designated as a short-term treatment course for acute respiratory exacerbations. Official information describes its use as being carried out over a limited duration, usually 7 to 10 days.

Q: Can Ambrocol interfere with birth control pills?

The official interaction section states if there are documented interaction patterns with oral hormonal contraceptives. When a major interaction is not explicitly listed in regulatory warnings, a mandatory warning regarding this interaction does not apply.

Q: Does Ambrocol have any known interactions with alcohol?

Official regulatory documentation typically includes an explicit statement regarding alcohol consumption. This information will describe whether alcohol should be avoided or restricted while taking Ambrocol.

How should Ambrocol be stored and disposed of?

How to Store and Dispose of Ambrocol?

Ambrocol (Ambroxol/Clenbuterol) must be stored and handled according to specific official regulatory guidelines to maintain its stability and ensure safety.

Storage Requirements

The medication should be stored at room temperature, which is a temperature not exceeding 30 C. It is mandatory to protect the product from light and avoid damp areas. The oral formulation must not be frozen. The container must be kept tightly closed, and the medicine must always be stored out of the sight and reach of children and pets.

Disposal Instructions

Expired or unused Ambrocol must be disposed of in accordance with local regulations. It is prohibited to flush the medicine down the sink or toilet, as disposal into wastewater systems must be avoided. The preferred method for discarding unused medication is utilizing community drug take-back programs.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ambrocol found in:

A-Z Index: